Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
Delforge M, Otero PR, Shah N, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Devlen J, Miera M, Gerould H, Campbell TB, Munshi NC. Delforge M, et al. Among authors: lanar s. Leuk Res. 2023 Jun;129:107074. doi: 10.1016/j.leukres.2023.107074. Epub 2023 Apr 3. Leuk Res. 2023. PMID: 37087950 Free article. Clinical Trial.
Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.
Shah N, Delforge M, San-Miguel J, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Miera M, Williams A, Murphy R, Devlen J, Hege K, Campbell TB, Munshi NC. Shah N, et al. Among authors: lanar s. Leuk Res. 2022 Sep;120:106921. doi: 10.1016/j.leukres.2022.106921. Epub 2022 Jul 21. Leuk Res. 2022. PMID: 35930999 Free article.
Drivers of and Barriers to Adherence to Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Treatment Management Plans: A Multi-National Qualitative Study.
Giocanti-Aurégan A, García-Layana A, Peto T, Gentile B, Chi GC, Mirt M, Kosmas CE, Lambert J, Lanar S, Lewis HB, Holekamp NM. Giocanti-Aurégan A, et al. Among authors: lanar s. Patient Prefer Adherence. 2022 Mar 3;16:587-604. doi: 10.2147/PPA.S347713. eCollection 2022. Patient Prefer Adherence. 2022. PMID: 35264847 Free PMC article.
Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy.
Anderson J, Levy DS, Lumry W, Koochaki P, Lanar S, Henry Li H. Anderson J, et al. Among authors: lanar s. Allergy Asthma Clin Immunol. 2021 Jun 27;17(1):60. doi: 10.1186/s13223-021-00550-5. Allergy Asthma Clin Immunol. 2021. PMID: 34176500 Free PMC article.
Integrating qualitative interviews in drug development and the use of qualitative evidence in product labelling and health technology assessments: a review.
Michel AS, Kamudoni P, Marrel A, Adiutori R, Desvignes-Gleizes C, Lanar S, Schache P, Spies E, Park J. Michel AS, et al. Among authors: lanar s. Front Med (Lausanne). 2023 Jun 20;10:1197529. doi: 10.3389/fmed.2023.1197529. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37415771 Free PMC article. Review.